Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 20 April 2018, 17:50 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting

TOKYO, Apr 20, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa) and rufinamide (product name: Inovelon, U.S. product name: BANZEL) will be presented at the 2018 Annual American Academy of Neurology (AAN) Meeting to be held from April 21 to 27, 2018 in Los Angeles, California in the United States.

As major presentations, six poster presentations will be given for perampanel including on an analysis of clinical factors associated with maintaining long-term seizure freedom in global Phase III studies for adjunctive perampanel in patients with partial onset seizures (POS), as well as on an evaluation of perampanel as monotherapy using the results from these same Phase III studies. Regarding rufinamide, two poster presentations will be given including on an integrated analysis of clinical studies on rufinamide in patients with Lennox-Gastaut syndrome (LGS).

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is available in tablet form to be taken once daily, and a new oral suspension formulation is also available in the United States. A highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors, it is approved in countries around the world as an adjunctive therapy for the treatment of POS with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is approved for use as monotherapy for POS in patients with epilepsy 12 years of age and older in the United States. In addition, Eisai has filed an application seeking approval for an indication expansion covering monotherapy and adjunctive use of perampanel in the treatment of POS with or without secondary generalized seizures in pediatric patients (2 years of age and older) in the United States.

Rufinamide is believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in the brain involved in the overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state. The agent is approved as an adjunctive therapy to other AEDs in the treatment of seizures associated with LGS in Europe and the United States. In Japan, the agent is approved as an adjunctive therapy to other AEDs in the treatment of tonic and atonic seizures associated with LGS when therapy with other AEDs is considered inadequate.

Furthermore, regarding the anti-Abeta antibody aducanumab which is being jointly developed as of October 22, 2017 by Eisai and Biogen Inc., platform presentations will be made on long term administration of aducanumab in a Phase Ib clinical study currently being conducted by Biogen.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to provide new solutions for those living with epilepsy and increase the breadth of patients for which perampanel may provide seizure-freedom in order to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department
Eisai Co., Ltd.
+81-3-3817-5120


Apr 20, 2018 17:50 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 18, 2019 12:32 HKT/SGT
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18, 2019 12:11 HKT/SGT
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
May 29, 2019 09:05 HKT/SGT
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 17, 2019 15:34 HKT/SGT
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 16, 2019 07:37 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 10, 2019 12:34 HKT/SGT
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10, 2019 11:55 HKT/SGT
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 9, 2019 11:33 HKT/SGT
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 9, 2019 11:06 HKT/SGT
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 8, 2019 08:37 HKT/SGT
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: